HRMY · NASDAQ
Harmony Biosciences Holdings (HRMY) Stock Price & Fundamentals
Harmony Biosciences Holdings (HRMY) closed at $410.59 on Oct 9, 2026, up 0.28% from the previous close of $409.44.
Share price, past year
1Y +17.56%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $410.59 |
| Sep 30, 2026 | $401.99 |
| Aug 31, 2026 | $407.16 |
| Jul 31, 2026 | $390.68 |
| Jun 30, 2026 | $397.11 |
| May 29, 2026 | $366.96 |
| Apr 30, 2026 | $362.51 |
| Mar 31, 2026 | $370.88 |
| Feb 27, 2026 | $388.75 |
| Jan 30, 2026 | $375.16 |
| Dec 31, 2025 | $370.75 |
| Nov 28, 2025 | $365.12 |
| Oct 31, 2025 | $358.98 |
Key statistics
- Market cap
- $23.86B
- P/E (TTM)
- 133.3
- EPS (TTM)
- $3.08
- Revenue (TTM)
- $959.90M
- Net income (TTM)
- $181.27M
- Shares outstanding
- 58.1M
- Dividend yield
- —
- 52-week range
- $346.02 – $414.45
Harmony Biosciences Holdings's market cap is $23.86B, based on a share price of $410.59 and 58.1M shares outstanding as of Jun 30, 2026.
Financials
Harmony Biosciences Holdings reported revenue of $868.45M for fiscal 2025, up 21.51% from fiscal 2024.
Harmony Biosciences Holdings earned net income of $158.69M in fiscal 2025, a net margin of 18.3%.
Fiscal 2025 revenue was the highest in the 7 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $868.45M | +21.5% | $158.69M | 18.3% | $2.71 | $347.89M |
| FY2024ended Dec 31, 2024 | $714.73M | +22.8% | $145.49M | 20.4% | $2.51 | $218.67M |
| FY2023ended Dec 31, 2023 | $582.02M | +32.9% | $128.85M | 22.1% | $2.13 | $219.08M |
| FY2022ended Dec 31, 2022 | $437.86M | +43.4% | $181.47M | 41.4% | $2.97 | $144.29M |
| FY2021ended Dec 31, 2021 | $305.44M | +91.2% | $34.60M | 11.3% | $0.58 | $98.26M |
| FY2020ended Dec 31, 2020 | $159.74M | +2,564.6% | −$36.94M | −23.1% | −$2.48 | −$2.99M |
| FY2019ended Dec 31, 2019 | $6.00M | — | −$151.98M | −2,535.1% | −$24.07 | −$75.59M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $261.28M | $75.43M | $1.28 |
| Q1 FY2026ended Mar 31, 2026 | $215.39M | $32.49M | $0.55 |
| Q4 FY2025ended Dec 31, 2025 | $243.78M | $22.49M | $0.38 |
| Q3 FY2025ended Sep 30, 2025 | $239.46M | $50.87M | $0.87 |
| Q2 FY2025ended Jun 30, 2025 | $200.49M | $39.78M | $0.68 |
| Q1 FY2025ended Mar 31, 2025 | $184.73M | $45.56M | $0.78 |
| Q4 FY2024ended Dec 31, 2024 | $201.27M | $49.48M | $0.85 |
| Q3 FY2024ended Sep 30, 2024 | $186.04M | $46.09M | $0.79 |
Company profile
- Name
- Harmony Biosciences Holdings, Inc.
- Ticker
- HRMY
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 630 W Germantown Pike, Suite 215, Plymouth Meeting, PA 19462
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001802665
Recent SEC filings
- Aug 4, 2026
- Aug 4, 2026
- Jul 16, 2026
- May 14, 2026
- May 7, 2026
- May 7, 2026
- Apr 14, 2026
- Apr 2, 2026
Frequently asked questions
What is Harmony Biosciences Holdings's stock price?
Harmony Biosciences Holdings (HRMY) closed at $410.59 on Oct 9, 2026, up 0.28% from the previous close of $409.44.
What is Harmony Biosciences Holdings's market cap?
Harmony Biosciences Holdings's market cap is $23.86B, based on a share price of $410.59 and 58.1M shares outstanding as of Jun 30, 2026.
How much revenue does Harmony Biosciences Holdings make?
Harmony Biosciences Holdings reported revenue of $868.45M for fiscal 2025, up 21.51% from fiscal 2024.
What is HRMY's P/E ratio?
Harmony Biosciences Holdings's price-to-earnings ratio is 133.3, based on trailing twelve-month diluted EPS of $3.08.
Does Harmony Biosciences Holdings pay a dividend?
Harmony Biosciences Holdings's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Harmony Biosciences Holdings, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures